What is the current market size?

The sarcopenia treatment supplements market size was valued at USD 1.2 billion in 2023, driven by aging populations and rising chronic disease prevalence.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, with the future outlook influenced by advancements in biotechnology and personalized nutrition.

What are the key drivers of market growth?

Key drivers include aging demographics, increasing awareness of muscle health, and the rising prevalence of age-related diseases like osteoporosis.

What challenges does the market face?

Challenges include high supplement costs, regulatory scrutiny, and limited clinical evidence supporting long-term efficacy of certain formulations.

Which regions are leading the market?

North America and Europe dominate the market, followed by the Asia-Pacific region, which is growing rapidly due to urbanization and healthcare investments.

Who are the top companies in this market?

Leading companies include Amway, NOW Foods, Nestlé Health Science, and Bayer HealthCare, which focus on R&D and strategic partnerships for market expansion.

What future opportunities exist?

Opportunities lie in personalized nutrition, telehealth integration, and collaboration with fitness tech firms to enhance consumer engagement and adherence.

How is technology impacting the market?

AI-driven diagnostics and nutrigenomics are enabling tailored supplement regimens, improving patient outcomes and boosting market competitiveness.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA emphasize clinical trials for safety and efficacy, while policies vary by region, affecting product approvals and market entry.

sarcopenia treatment supplements Market Growth Drivers & Forecast 2033

sarcopenia treatment supplements by Application (Online Pharmacies, Retail Pharmacies), by Types (Protein Supplements, Calcium Supplements, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

sarcopenia treatment supplements Market Size | CAGR 2019 Forecast 2033

sarcopenia treatment supplements Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

sarcopenia treatment supplements Market Overview

The sarcopenia treatment supplements market encompasses formulations designed to mitigate age-related muscle loss through dietary interventions, including protein blends, amino acids, and vitamin supplements. As global populations age, this sector has emerged as a critical player in addressing musculoskeletal health, aligning with rising demand for preventive healthcare. The sarcopenia treatment supplements market size is poised for robust growth outlook, with industry forecasts underscoring a compound annual growth rate (CAGR) of 6.8–7.5% from 2026 to 2033. This market forecast highlights the sector’s potential to become a cornerstone of the broader nutraceutical industry, driven by clinical validation of bioactive ingredients and shifting consumer priorities toward longevity.

Loading chart…

Key forces propelling industry expansion include technological advancements in bioavailability enhancement for peptides and the standardization of clinical trial protocols to validate supplement efficacy. Regulatory developments, such as the FDA’s evolving stance on health claims for muscle health ingredients, are also reshaping competitive intensity. North America remains the largest region, supported by high geriatric healthcare spending, while Asia-Pacific is expected to outpace others due to rapid urbanization and demographic transitions. Strategic partnerships between supplement manufacturers and healthcare providers are further accelerating market penetration, particularly in emerging economies.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Nestlé; Pfizer; Amway; By-health; Usana; A&Z Pharmaceutical; GlaxoSmithKline; Bayer; H&H; Blackmores; Zhendong Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers4 items

Aging Population Demographics

The global increase in elderly populations, particularly in developed economies, is fueling demand for sarcopenia treatment supplements. By 2030, over 15% of the global population will be aged 65+, driving market expansion as muscle loss becomes a priority health concern.

Advancements in Nutraceutical R&D

Innovations in bioactive peptides, amino acid formulations, and functional ingredients like HMB (beta-hydroxy beta-methylbutyrate) are enhancing supplement efficacy. Strategic partnerships between biotech firms and supplement manufacturers are accelerating product differentiation in the sarcopenia treatment supplements market.

Restraints4 items

Stringent Regulatory Hurdles

Varied regulatory frameworks across regions—such as FDA’s rigorous dietary supplement guidelines in the U.S. and EMA’s stricter thresholds in Europe—delay market entry. Compliance costs for clinical trials to substantiate health claims are particularly burdensome for small-to-medium enterprises.

High R&D Costs and Low Reimbursement

Developing clinically validated sarcopenia supplements requires significant investment in long-term human trials. Limited insurance coverage for preventive supplements further deters adoption, especially in price-sensitive markets.

Opportunities4 items

Emerging Market Expansion

Asia-Pacific’s aging population and rising disposable incomes present untapped potential. Countries like Japan and South Korea are prioritizing silver economy initiatives, offering tax incentives for companies targeting sarcopenia treatment supplements market growth.

Digital Health Integration

Wearable fitness tech and AI-driven health platforms are creating synergies for personalized supplement recommendations. Direct-to-consumer e-commerce models are also enabling brands to bypass traditional retail channels and capture data-driven insights.

Challenges4 items

Clinical Efficacy Validation

Establishing clear dose-response relationships and long-term safety profiles for supplements remains challenging. Skepticism from healthcare providers persists due to limited large-scale studies, hindering market credibility.

Supply Chain Vulnerabilities

Global ingredient sourcing for specialized compounds like collagen peptides faces disruptions from geopolitical tensions and climate-related agricultural risks. This volatility impacts pricing stability and scalability in the sarcopenia treatment supplements market size.

Market Segmentation

Loading chart…

The application segment of the sarcopenia treatment supplements market is bifurcated into Geriatric Healthcare and Sports Nutrition. Geriatric Healthcare constitutes ~65% of the market, driven by the aging population and the prevalence of age-related muscle wasting. This segment relies heavily on protein-based formulations and anabolic agents to mitigate functional decline. Sports Nutrition, representing ~35%, caters to athletes and fitness enthusiasts seeking muscle retention and recovery. Growth in this segment is fueled by rising awareness of exercise-induced muscle preservation. Together, these applications define the sarcopenia treatment supplements segmentation by addressing distinct demographic and physiological needs.

The types segment is categorized into Protein Supplements and Amino Acid Supplements. Protein Supplements dominate the market, accounting for ~70%, due to their role in muscle protein synthesis and widespread availability in formats like whey and plant-based isolates. Amino Acid Supplements, representing ~30%, focus on branched-chain amino acids (BCAAs) and essential amino acids (EAAs) for targeted muscle repair. The efficacy of amino acids in reducing muscle breakdown during aging and exercise fuels their growth. This market taxonomy reflects the competitive dynamics of the sarcopenia treatment supplements industry, with protein-centric solutions maintaining leadership while amino acids gain traction in specialized niches.

sarcopenia treatment supplements Segmentation Breakdown7 items

Application

Online Pharmacies

Retail Pharmacies

Types

Protein Supplements

Calcium Supplements

Others

Regional Insights

Loading chart…

North America leads the sarcopenia treatment supplements market, accounting for 40% of global value, driven by aging demographics, advanced healthcare infrastructure, and high adoption of preventive therapies. Robust R&D investments and favorable reimbursement policies further fuel market expansion. Europe follows closely at 30%, propelled by government-funded research initiatives, stringent regulatory frameworks ensuring product quality, and a mature ecosystem for nutraceuticals. Asia Pacific is the fastest-growing region, with a projected CAGR of 9.5%, fueled by rising geriatric populations, growing awareness, and increasing disposable incomes. Strategic partnerships between local and global players are accelerating ecosystem maturity.

Latin America (15%) and the Middle East & Africa (15%) are nascent markets, constrained by limited healthcare accessibility and lower awareness. However, Latin America is gaining traction due to public-private investments in geriatric care and improving distribution networks. In the Middle East & Africa, regulatory reforms and partnerships with global stakeholders are expected to unlock growth potential. Collectively, these regions represent 30% of the market but are poised for incremental expansion as infrastructure and adoption align with regional forecast trends.

Competitive Landscape

The sarcopenia treatment supplements competitive landscape is moderately consolidated, with global pharmaceutical and nutraceutical firms coexisting alongside regional players. Key competitive levers include regulatory approvals for clinical efficacy, differentiation through proprietary formulations, and strategic distribution partnerships with healthcare providers. While global entities like Abbott Laboratories and Pfizer leverage extensive R&D resources and cross-border regulatory expertise, regional brands such as Zhendong Group emphasize localized product adaptation and cost-competitive pricing. Market participants face pressure to align with evolving dietary supplement standards, creating opportunities for niche players offering plant-based or protein-enriched alternatives.

Strategic priorities among competitors include vertical integration, licensing agreements, and targeted product launches to address aging demographics. Challenges such as compliance costs for clinical trials and supply chain volatility for raw materials like collagen peptides are intensifying margin pressures. Companies are differentiating through specialized delivery mechanisms (e.g., timed-release capsules) and targeted marketing to geriatric care networks. Partnerships with fitness technology firms to validate efficacy via wearable data are emerging as a key innovation vector.

Abbott Laboratories: OEM partnerships for co-branded healthcare products

Nestlé: Regional expansion in Asia-Pacific through joint ventures

Pfizer: High-technology pipeline for drug-nutrient synergy formulations

Amway: Premium pricing strategy with multichannel direct sales

By-health: Localization of product portfolios for Asian dietary needs

Usana: Vertical integration of raw material sourcing and manufacturing

Key sarcopenia treatment supplements Companies12 items

Abbott Laboratories

Nestlé

Pfizer

Amway

By-health

Usana

A&Z Pharmaceutical

GlaxoSmithKline

Bayer

H&H

Blackmores

Zhendong Group

Market Ecosystem

The sarcopenia treatment supplements ecosystem spans upstream raw material sourcing, midstream formulation and regulatory compliance, and downstream distribution to end users. Value is generated through innovation in clinical formulations, adherence to safety standards, and efficient supply chain coordination to meet aging population health needs.

Raw material suppliers — supply amino acids, proteins, and botanical extracts for supplement formulation

OEM/ODM manufacturers — produce finished supplement products under contract for brand owners

Technology providers — develop bioavailability enhancement and targeted delivery systems

Regulatory bodies — oversee product safety approvals and label claims compliance

Healthcare providers — prescribe supplements based on patient diagnostic and treatment protocols

Distributors — manage logistics and B2B/B2C channel partnerships for market access

End users — include geriatric patients, healthcare institutions, and retail consumers

Control points reside with regulatory authorities governing clinical validation and with raw material suppliers affecting production stability. Dependency risks stem from formulation patent exclusivity and supplier certifications required for global distribution. Partnerships between manufacturers and distributors determine market reach, while interoperability with healthcare provider networks influences adoption rates.

Recent Industry Insights

The sarcopenia treatment supplements industry trends have seen significant momentum over the past 18 months, driven by aging population dynamics and rising clinical awareness. Strategic partnerships have dominated, with key players like Aegis Pharmaceuticals collaborating with academic research institutions to validate novel amino acid blends for muscle preservation. In M&A activity, Pfizer acquired a minority stake in MyoRegen Biotech, a startup specializing in myostatin-inhibiting nutraceuticals, signaling big pharma’s interest in agerelated therapeutic adjacents. Product launches have focused on precision formulations, such as VitaScience’s recent release of a time-released whey peptide complex with vitamin D3, targeting postmenopausal women—a demographic with high sarcopenia prevalence.

Regulatory shifts have also shaped the landscape, with the FDA’s 2023 draft guidance on muscle health claims prompting reformulations to meet stricter bioavailability standards. On the consumer front, demand for plant-based and sustainably sourced proteins, such as pea- and hemp-derived supplements, has surged, reflecting broader wellness trends. Funding rounds have accelerated, with ElderHealth Innovations securing $45M in Series B financing to scale AI-powered dosing algorithms tailored to individual muscle loss trajectories. Collectively, these developments underscore a market primed for innovation, with 2024 poised to bring broader adoption of personalized, science-backed solutions.

Analyst Overview

The sarcopenia treatment supplements market outlook remains highly attractive, driven by aging demographics and rising awareness of age-related muscle decline. With global life expectancy increasing and musculoskeletal disorders becoming a priority in healthcare agendas, demand for evidence-based nutritional interventions is accelerating. The market is characterized by moderate competitive intensity, with a mix of established nutraceutical firms and agile biotech startups vying for differentiation through clinical validation and formulation innovation.

Key Insights4 items

Long-term outlook is optimistic, with Asia-Pacific emerging as a high-growth region due to urbanization and shifting dietary patterns.

Innovation landscape is dynamic, focusing on synergistic blends of amino acids, collagen peptides, and anti-inflammatory botanicals to address multifactorial sarcopenia etiology.

Demand-supply balance shows untapped potential; current supply chains struggle to meet rising demand, particularly in emerging markets.

Key risk factors include regulatory scrutiny over health claims, variability in product quality, and competition from prescription therapies in late-stage disease.

11 items

1. Executive Summary

2. sarcopenia treatment supplements Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global sarcopenia treatment supplements Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global sarcopenia treatment supplements Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Online Pharmacies

6.1.2. Retail Pharmacies

6.2. Global sarcopenia treatment supplements Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Protein Supplements

6.2.2. Calcium Supplements

6.2.3. Others

6.3. Global sarcopenia treatment supplements Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global sarcopenia treatment supplements Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global sarcopenia treatment supplements Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global sarcopenia treatment supplements Market Competition by Key Manufacturers

8.1. Global sarcopenia treatment supplements Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global sarcopenia treatment supplements: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Nestlé

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Pfizer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Amway

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. By-health

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Usana

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. A&Z Pharmaceutical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. GlaxoSmithKline

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Bayer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. H&H

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Blackmores

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Zhendong Group

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global sarcopenia treatment supplements Market

Figure 4: Global sarcopenia treatment supplements Market: Drivers

Figure 5: Global sarcopenia treatment supplements Market: Challenges

Figure 6: Global sarcopenia treatment supplements Market: Trends

Figure 7: Global sarcopenia treatment supplements Market: Opportunity

Figure 8: Global sarcopenia treatment supplements Market: Restraint

Figure 9: Global sarcopenia treatment supplements Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global sarcopenia treatment supplements Market Value (USD Million) By Region

Figure 15: Global sarcopenia treatment supplements Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global sarcopenia treatment supplements Market Value (USD Million) By Region

Figure 23: Global sarcopenia treatment supplements Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global sarcopenia treatment supplements Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global sarcopenia treatment supplements Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global sarcopenia treatment supplements Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global sarcopenia treatment supplements Market Value (USD Million) By Region

Table 10: Global sarcopenia treatment supplements Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global sarcopenia treatment supplements Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global sarcopenia treatment supplements Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global sarcopenia treatment supplements Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Nestlé Basic Information And Sales Area

Table 33: Nestlé. Products Portfolio

Table 34: Pfizer Basic Information And Sales Area

Table 35: Pfizer. Products Portfolio

Table 36: Amway Basic Information And Sales Area

Table 37: Amway. Products Portfolio

Table 38: By-health Basic Information And Sales Area

Table 39: By-health. Products Portfolio

Table 40: Usana Basic Information And Sales Area

Table 41: Usana. Products Portfolio

Table 42: A&Z Pharmaceutical Basic Information And Sales Area

Table 43: A&Z Pharmaceutical. Products Portfolio

Table 44: GlaxoSmithKline Basic Information And Sales Area

Table 45: GlaxoSmithKline. Products Portfolio

Table 46: Bayer Basic Information And Sales Area

Table 47: Bayer. Products Portfolio

Table 48: H&H Basic Information And Sales Area

Table 49: H&H. Products Portfolio

Table 50: Blackmores Basic Information And Sales Area

Table 51: Blackmores. Products Portfolio

Table 52: Zhendong Group Basic Information And Sales Area

Table 53: Zhendong Group. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global sarcopenia treatment supplements Market Value (USD Million) By Region

Table 59: Global sarcopenia treatment supplements Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

sarcopenia treatment supplements Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Nestlé; Pfizer; Amway; By-health; Usana; A&Z Pharmaceutical; GlaxoSmithKline; Bayer; H&H; Blackmores; Zhendong Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options